Logo

GE Healthcare to Exclusively Distribute DiscoveRx s HitHunter cAMP Assays Worldwide

May 24, 2006

NEW YORK, May 24 (GenomeWeb News) - GE Healthcare signed an exclusive distribution agreement with DiscoveRx for its HitHunter cAMP assays, GE Healthcare said today.

Terms of the deal call for GE to exclusivelty distribute DiscoveRx's HitHunter cAMP Enzyme Fragment Complementation-based assays worldwid. The deal also expands GE's rights to distribute DiscoveRx's portfolio of kinase assays, with exclusive distribution in the Asia-Pacific region.

 

The cAMP assays are designed for high throughput, non-radioactive screening of compounds in drug discovery. The homogeneous cell-based assays are used to screen for G-protein coupled receptor activation in a microplate-based format.
 

Financial details were not disclosed.

Breaking News
The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.